IL13 and Alzheimer disease: Further, IL-13-neutralizing antibody tralokinumab, which is approved in Europe for the treatment of AD, was reported to shift the stratum corneum lipid profile from lesional to non-lesional type, suggesting the underlying role in improving barrier function [83].